Survival Differences in High-Risk Prostate Cancer by Age

被引:0
|
作者
Garcia-Fuentes, Clara [1 ]
Guijarro, Ana [1 ]
Hernandez, Virginia [1 ]
Gonzalo-Balbas, Alvaro [1 ]
Jimenez-Alcaide, Estibaliz [1 ,3 ]
de la Pena, Enrique [1 ]
Perez-Fernandez, Elia [2 ]
Llorente, Carlos [1 ]
机构
[1] Hosp Univ Fdn Alcorcon, Dept Urol, Madrid, Spain
[2] Hosp Univ Fdn Alcorcon, Res Unit, Madrid, Spain
[3] Hosp Univ Fdn Alcorcon, Dept Urol, Avda Budapest 1, Alcorcon 28922, Madrid, Spain
关键词
high-risk prostate cancer; age groups; survival differences; LONG-TERM SURVIVAL; RADICAL PROSTATECTOMY; RADIATION-THERAPY; MEN; COMORBIDITY; RADIOTHERAPY; IMPACT; DEATH;
D O I
10.22037/uj.v20i.7393
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Age is an established determining factor in survival in low-risk prostate cancer (PC), being this evidence weaker in high-risk tumors. Our aim is to evaluate the survival of patients with high-risk PC treated with curative intent and to identify differences across ages at diagnosis.Methods: We did a retrospective analysis of patients with high-risk PC treated with surgery (RP) or radiotherapy (RDT) excluding N+ patients. We divided patients by age groups: < 60, 60-70, and > 70 years. We performed a comparative survival analysis. A multivariate analysis adjusted for clinically relevant variables and initial treat-ment received was performed.Results: Of a total of 2383 patients, 378 met the selection criteria with a median follow-up of 8.9 years: 38 (10.1%) < 60 years, 175 (46.3%) between 60-70 years, and 165 (43.6%) >70 years. Initial treatment with surgery was predominant in the younger group (RP:63.2%, RDT:36.8%), and with radiotherapy in the older group (RP:17%, RDT:83%) (p = 0.001). In the survival analysis, significant differences were observed in overall survival, with better results for the younger group. However, these results were reversed in biochemical recurrence-free survival, with patients < 60 years presenting a higher rate of biochemical recurrence at 10 years. In the multivariate analysis, age behaved as an independent risk variable only for overall survival, with a HR of 2.8 in the group >70 years (95%CI: 1.22-6.5; p = 0.015).Conclusion: In our series, age appeared to be an independent prognostic factor for overall survival, with no differ-ences in the rest of the survival rates.
引用
收藏
页码:215 / 221
页数:7
相关论文
共 50 条
  • [41] The role of surgery for high-risk prostate cancer
    Ucer, Oktay
    Muezzinoglu, Talha
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2014, 13 (01): : 21 - 24
  • [42] Approach to the Patient with High-Risk Prostate Cancer
    Mossanen, Matthew
    Krasnow, Ross E.
    Nguyen, Paul L.
    Trinh, Quoc D.
    Preston, Mark
    Kibel, Adam S.
    UROLOGIC CLINICS OF NORTH AMERICA, 2017, 44 (04) : 635 - +
  • [43] Management of High-Risk Localised Prostate Cancer
    Ozen, Haluk
    Yazici, Sertac
    Inci, Kubilay
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (05) : 439 - 447
  • [44] Editorial: Optimizing Local Therapy for High-Risk Prostate Cancer: Evidence and Emerging Options
    Zaorsky, Nicholas G.
    Spratt, Daniel E.
    Kishan, Amar U.
    Culp, Stephen H.
    Showalter, Timothy N.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [45] The Effect of Age on Prostate Cancer Survival
    Clark, Roderick
    Vesprini, Danny
    Narod, Steven A.
    CANCERS, 2022, 14 (17)
  • [46] Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?
    Saad, Akram
    Goldstein, Jeffrey
    Lawrence, Yaacov R.
    Spieler, Benjamin
    Leibowitz-Amit, Raya
    Berger, Raanan
    Davidson, Tima
    Urban, Damien
    Tsang, Lev
    Alezra, Dror
    Weiss, Ilana
    Symon, Zvi
    RADIATION ONCOLOGY, 2017, 12
  • [47] ACR Appropriateness Criteria® Locally Advanced, High-Risk Prostate Cancer
    McLaughlin, Patrick W.
    Liss, Adam L.
    Nguyen, Paul L.
    Assimas, Dean G.
    D'Amico, Anthony V.
    Gottschalk, Alexander R.
    Gustafson, Gary S.
    Keol, Sameer R.
    Liauw, Stanley L.
    Lloyd, Shane
    Movsas, Benjamin
    Prestidg, Bradley R.
    Showalter, Timothy N.
    Taira, Al V.
    Vapiwal, Neha
    Davi, Brian J.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (01): : 1 - 10
  • [48] Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study
    Joniau, Steven
    Briganti, Alberto
    Gontero, Paolo
    Gandaglia, Giorgio
    Tosco, Lorenzo
    Fieuws, Steffen
    Tombal, Bertrand
    Marchioro, Giansilvio
    Walz, Jochen
    Kneitz, Burkhard
    Bader, Pia
    Frohneberg, Detlef
    Tizzani, Alessandro
    Graefen, Markus
    van Cangh, Paul
    Karnes, R. Jeffrey
    Montorsi, Francesco
    Van Poppel, Hein
    Spahn, Martin
    EUROPEAN UROLOGY, 2015, 67 (01) : 157 - 164
  • [49] Thwarting High-risk Prostate Cancer: The Right Treatments for the Right Patients
    Cooperberg, Matthew R.
    EUROPEAN UROLOGY, 2012, 61 (06) : 1107 - 1109
  • [50] Safety and Efficacy of Carbon-Ion Radiotherapy for Elderly Patients with High-Risk Prostate Cancer
    Hiroshima, Yuichi
    Ishikawa, Hitoshi
    Iwai, Yuma
    Wakatsuki, Masaru
    Utsumi, Takanobu
    Suzuki, Hiroyoshi
    Akakura, Koichiro
    Harada, Masaoki
    Sakurai, Hideyuki
    Ichikawa, Tomohiko
    Tsuji, Hiroshi
    CANCERS, 2022, 14 (16)